Thyroid Eye Disease Clinical Trials

108 clinical trials for Thyroid Eye Disease across international registries, including 22 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease — RECRUITING · PHASE4
• An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease — RECRUITING · PHASE2
• A Study of IBI3031 in Participants With Thyroid Eye Disease — RECRUITING · PHASE1
• A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants with Thyroid Eye Disease. — RECRUITING · PHASE2
• VRDN-003-301: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED) — RECRUITING · PHASE3
• MHB018A Treatment in Patients With Chronic Thyroid Eye Disease — RECRUITING · PHASE3
• Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease — RECRUITING · PHASE3
• Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting — RECRUITING
• Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. — RECRUITING · NA
• A Study of GenSci098 in Subjects With Active Thyroid Eye Disease — RECRUITING · PHASE1
• A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease — RECRUITING · PHASE3
• A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease — RECRUITING · PHASE3
• A PHASE 1/2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 732 IN HEALTHY SUBJECTS AND SUBJECTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE — RECRUITING · PHASE1
• Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF EFGARTIGIMOD PH20 SC ADMINISTERED BY PREFILLED SYRINGE IN ADULT PARTICIPANTS WITH THYROID EYE DISEASE — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS TEPROTUMUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE — RECRUITING · PHASE3
• Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease — RECRUITING · NA
• The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction — RECRUITING
• A MULTICENTER PHASE 2B RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED DOSE-RANGING STUDY OF TOUR006 IN PARTICIPANTS WITH THYROID EYE DISEASE — RECRUITING · PHASE2
• A PHASE III, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE THYROID EYE DISEASE — RECRUITING · PHASE3
• A PHASE 2B, RANDOMIZED, DOUBLE-MASK, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF LINSITINIB IN SUBJECTS WITH ACTIVE, MODERATE TO SEVERE THYROID EYE DISEASE (TED) — RECRUITING · PHASE2
• A MULTIPLE ASCENDING DOSE (MAD) SAFETY, TOLERABILITY AND EFFICACY STUDY OF VRDN-001, A HUMANIZED MONOCLONAL ANTIBODY DIRECTED AGAINST THE IGF-1 RECEPTOR, IN NORMAL HEALTHY VOLUNTEERS (NHVS) AND SUBJECTS WITH THYROID EYE DISEASE (TED) — RECRUITING
• An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up — TERMINATED · PHASE2
• An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 — COMPLETED · PHASE3
• A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) — COMPLETED · PHASE3
• Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease — NOT_YET_RECRUITING · PHASE1
• An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) — COMPLETED · PHASE3
• A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease — COMPLETED · PHASE3
• A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease — ACTIVE_NOT_RECRUITING · PHASE1
• A randomized, double-masked, controlled, safety and tolerability study of VRDN-003 in participants with thyroid eye disease (TED) — TERMINATED · PHASE3
• Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease — COMPLETED · PHASE3
• A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease — NOT_YET_RECRUITING · PHASE3
• A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease — NOT_YET_RECRUITING · PHASE3
• A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease — ACTIVE_NOT_RECRUITING · PHASE3
• A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) — COMPLETED · PHASE3
• A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease — ACTIVE_NOT_RECRUITING · PHASE1
• Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease) — COMPLETED
• Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease — NOT_YET_RECRUITING · PHASE3
• Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) — NOT_YET_RECRUITING
• Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) — NOT_YET_RECRUITING
• A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) — ACTIVE_NOT_RECRUITING · PHASE3
• An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects with Moderate-to-Severe Active Thyroid Eye Disease — TERMINATED · PHASE2
• VRDN-003-302: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED) — TERMINATED · PHASE3
• Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease — TERMINATED · PHASE3
• A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) — TERMINATED · PHASE3
• An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) — ACTIVE_NOT_RECRUITING · PHASE3
• Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease — COMPLETED · PHASE3

Refine this search